CaryHealth Introduces Direct-to-Patient Access Program for Natroba in Collaboration with Cipher Pharmaceuticals CaryHealth, a leading provider of integrated digital healthcare solutions, has announced the launch of a new direct-to-patient (DTP) platform aimed at improving access to prescription treatments for common…
Amgen Shares Positive Topline Phase 3 Data for Subcutaneous TEPEZZA® in Adults with Moderate-to-Severe Active Thyroid Eye Disease Amgen (NASDAQ: AMGN) has announced positive topline results from a pivotal Phase 3 clinical trial evaluating a new method of administering TEPEZZA…
PureTech Reports Publication of Phase 2b ELEVATE IPF Trial Results in Leading Respiratory Medicine Journal PureTech Health plc, a clinical-stage biotherapeutics company focused on translating cutting-edge science into transformative therapies, has announced the publication of results from its Phase 2b…
Glycomine Announces Completion of Enrollment in Global Phase 2b POLAR Study Evaluating GLM101 for PMM2-CDG Glycomine, Inc. has announced the successful completion of patient enrollment in its Phase 2b POLAR clinical trial, a key milestone in the development of GLM101…
Vedanta Biosciences Confirms Phase 3 RESTORATiVE303 Study of VE303 Will Proceed as Planned Following Interim Analysis Vedanta Biosciences, a late clinical-stage company focused on developing microbiome-based oral therapies for gastrointestinal diseases, has announced encouraging progress in its pivotal Phase 3…
Thermo Fisher Scientific Introduces Unified Platform to Speed Biologics Development Thermo Fisher Scientific Inc., a global leader in scientific services and life sciences solutions, has introduced a next-generation, integrated cell line development (CLD) platform designed to accelerate biologics development timelines…
Alto Neuroscience Shares Topline Results from Phase 2 Proof-of-Concept Trial of ALTO-101 and Highlights Ongoing Pipeline Progress Alto Neuroscience, Inc. has announced topline results from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment…
LumaCyte’s Analytical Method Recognized in Newly Issued ISO Global Standard for Viral Vector Quantification LumaCyte has announced a significant milestone for its proprietary analytical technology, revealing that its approach has been formally incorporated into the newly published global standard for…
Introduces FFPE-Compatible Barcoding Innovation Enabling Whole Transcriptome Single-Cell Analysis Parse Biosciences, a subsidiary of QIAGEN and a recognized leader in scalable single-cell sequencing technologies, has announced the commercial launch and immediate availability of its Evercode™ Whole Transcriptome FFPE kits. This…
Meiji Seika Pharma Invests in Centivax to Advance Universal Vaccine Innovation and Broaden Global Infectious Disease Preparedness Meiji Seika Pharma Co., Ltd., a leading Japanese pharmaceutical company with a long-standing commitment to advancing public health, has announced a strategic investment…
PepGen Reports Encouraging Phase 2 Data for PGN-EDODM1 in Myotonic Dystrophy Type 1, Advances Higher-Dose Cohort in FREEDOM2 Trial PepGen Inc., a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide therapeutics, has announced new clinical data from the 5 mg/kg…
Roche Launches cobas MPX-E, a 4-in-1 Donor Screening Assay to Strengthen Global Blood Supply Safety Roche has announced the availability of its cobas® MPX-E assay, a next-generation qualitative in vitro diagnostic test designed to detect and differentiate multiple high-risk viral…